Lexeo Therapeutics (LXEO) Research & Development (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Research & Development of $15.7 million for Q1 2026, little changed sequentially from $15.7 million in Q3 2025, and down 8.55% YoY from $17.2 million in Q1 2025.
Lexeo Therapeutics (LXEO) Research & Development (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Research & Development for 5 years, with the latest figure at $15.7 million in Q1 2026.
- Quarterly Research & Development fell 8.55% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.1 million (down 38.93% YoY) and the FY2025 annual result came in at $63.8 million, down 13.89% from the prior year.
- Research & Development held at $15.7 million in Q1 2026 per LXEO's latest filing, from $15.7 million in the prior quarter.
- Over five years, Research & Development peaked at $23.4 million in Q3 2024 and troughed at -$44.9 million in Q4 2023.
- A 5-year average of $11.7 million and a median of $15.7 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development sank 494.48% in 2023, then jumped 140.89% in 2024.
- Over 5 years, Research & Development stood at $11.4 million in 2022, then tumbled by 494.48% to -$44.9 million in 2023, then surged by 140.89% to $18.4 million in 2024, then slipped by 14.54% to $15.7 million in 2025, then gained by 0.05% to $15.7 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $15.7 million, $15.7 million, and $14.7 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | 19.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.03 Mn |
| Mar 31, 2026 | 15.70 Mn |
| Sep 30, 2025 | 15.70 Mn |
| Jun 30, 2025 | 14.72 Mn |
| Mar 31, 2025 | 17.17 Mn |
| Dec 31, 2024 | 18.37 Mn |
| Sep 30, 2024 | 23.42 Mn |
| Jun 30, 2024 | 16.56 Mn |
| Mar 31, 2024 | 15.74 Mn |
| Dec 31, 2023 | -44.92 Mn |
| Sep 30, 2023 | 17.25 Mn |
| Jun 30, 2023 | 11.24 Mn |
| Mar 31, 2023 | 16.44 Mn |
| Dec 31, 2022 | 11.39 Mn |
| Sep 30, 2022 | 15.36 Mn |